Core Viewpoint - Johnson & Johnson (J&J) has transitioned by spinning off its consumer health business to focus on innovative medicine and medtech, despite facing challenges from the loss of exclusivity of its top-selling drug, Stelara [1][2] Group 1: Company Performance - J&J has shown resilience by managing growth in its two main businesses despite the decline of Stelara [2] - The company's shares have increased by 15% this year, contrasting with the S&P 500's decline, indicating strong performance during uncertain market conditions [4] - J&J has 28 platforms or products generating at least $1 billion annually, allowing it to move past the Stelara exclusivity loss [5] Group 2: Financial Metrics - J&J's market capitalization is $572 billion, with a current share price range between $235.50 and $239.11 [6] - The company has a gross margin of 67.97% and a dividend yield of 2.19% [6] Group 3: Dividend Growth - J&J is recognized as a Dividend King, having increased its dividend for over 50 years, demonstrating a commitment to shareholder returns [7] - The company pays a dividend of $5.20, which is higher than the S&P 500's dividend yield of 1.1%, making it an attractive option for passive income [9]

Cheaper valuations this month are giving investors the opportunity to invest in ASX shares that are trading at much better value than before the sell-off.It’s a great time to buy, which is why I think investors should look at their favourite share ideas and consider this period as a time to buy (rather than panic). I’m going to point out two strong ideas to consider.Lovisa Holdings Ltd (ASX: LOV)There are few ASX shares that have become as global as jewellery retailer Lovisa, with a presence in numerous mar ...

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that by 2040, humanoid robots could create a market worth $250 trillion, representing a major shift in the global economy driven by AI innovation [2][3] - Major firms like PwC and McKinsey acknowledge the potential of AI to unlock multi-trillion-dollar opportunities, reinforcing the optimistic outlook on AI's economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is seen as a catalyst for redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, suggesting that it could be a significant investment opportunity [4][6] - Prominent figures in technology and investment, including Bill Gates and Warren Buffett, recognize AI as a major technological advancement with the potential for substantial social benefits [8]

Core Viewpoint - Johnson & Johnson's new oral psoriasis medication, Icotyde, has received FDA approval, positioning it as a competitive alternative to existing injectable treatments in the market [1][2]. Group 1: Product Overview - Icotyde is the first oral treatment approved for moderate to severe plaque psoriasis, an autoimmune condition characterized by rough skin patches [1]. - The drug targets the IL-23 receptor, similar to popular injectable treatments like Tremfya and Skyrizi, providing patients with an oral option [2]. Group 2: Market Potential - Johnson & Johnson anticipates that Icotyde could become the first-line systemic treatment for psoriasis, bridging the gap between topical treatments and injections [2]. - The company estimates that peak annual sales for Icotyde could exceed $5 billion once it is approved for additional autoimmune conditions, including psoriatic arthritis, ulcerative colitis, and Crohn's disease [5]. Group 3: Patient Demographics and Appeal - Approximately 8 million people in the U.S. suffer from plaque psoriasis, with 75% of patients not progressing to injections due to needle aversion [3]. - The company believes that Icotyde's simple once-daily oral dosage will be appealing to patients who are hesitant to use injectable treatments [4]. Group 4: Competitive Landscape - The approval of Icotyde comes as the psoriasis treatment market becomes increasingly competitive, with drugmakers developing advanced therapies beyond standard topical treatments [2]. - Rival injectable treatments, such as Tremfya and Skyrizi, are priced around $100,000 annually, highlighting the potential market disruption Icotyde could cause [4].

The U.S. Food and Drug Administration has approved Johnson & Johnson's oral pill for psoriasis, the company said on Wednesday, paving the way for a more convenient treatment option for patients with... ...

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met all primary endpoints and demonstrated a favorable safety profile in 2,500 patients $50 million milestone payment triggered by FDA approval; Protagonist is eligible to receive 6 - 10% royalties on sales and up to $580 million in future milestone payments Webcast and conference call to be held at 8:30 am ET on ...

FDA approval of ICOTYDEâ"¢ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide Accessibility StatementSkip Navigation Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE offers an innovative new option for patients with moderate-to-severe plaque psoriasis to address patients cycling on topical therapies in need of systemic tre ...

The Dow Jones Industrial Average (^DJI) was up 46.85 (0.10%) points today, reaching 46,993.26, as the market balanced a complex narrative of central bank policy and escalating geopolitical risks. The primary driver for today's session is the Federal Open Market Committee (FOMC) meeting, with investors closely monitoring Chair Jerome Powell’s afternoon press conference. While the Federal Reserve is widely expected to maintain interest rates, market participants are searching for clues regarding the impact of ...

Market Recap: A Green Day on Wall StreetU.S. equity markets found their footing on Tuesday, March 17, 2026, as investors shook off recent geopolitical jitters to push major indexes higher. The rebound comes after a volatile start to the month, with the S&P 500 (SPY) rising 0.6% to reach 6,741.72. The blue-chip Dow Jones Industrial Average (DIA) climbed 217.44 points, or approximately 0.5%, to finish at 47,163.85, while the tech-heavy Nasdaq Composite (QQQ) led the charge with a 0.7% gain, closing at 22,526. ...

Core Viewpoint - Johnson & Johnson has demonstrated strong performance in the healthcare sector, with a notable increase in share price over the past year and year-to-date [1] Summary by Category Company Performance - Johnson & Johnson's shares have increased by 48% over the past 12 months [1] - The company has seen a 16% rise in share price year-to-date [1]